
    
      Women diagnosed with familial hypercholesterolaemia (FH), treated at centres in Europe, South
      Africa and Australia, with pregnancy confirmed during the study observation period and who
      provide informed consent to participate in the study.

      Exposed subjects are women who received Repatha® during pregnancy and/or breastfeeding;
      unexposed subjects are women who have not received Repatha® during pregnancy and/or
      breast-feeding. In infants, exposure may occur in utero and/or via breast milk, within 15
      weeks following the date of Repatha® dosing in the mother
    
  